Nov 29 (Reuters) - X4 Pharmaceuticals Inc:
* X4 PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM 4WHIM GLOBAL, PIVOTAL PHASE 3 TRIAL OF ONCE-DAILY, ORAL MAVORIXAFOR IN WHIM SYNDROME
* MAVORIXAFOR WAS GENERALLY WELL TOLERATED IN TRIAL
* 4WHIM MET ITS PRIMARY ENDPOINT, WITH MAVORIXAFOR ACHIEVING CLINICAL AND STATISTICAL SUPERIORITY OVER PLACEBO WHEN MEASURING TATANC
* 4WHIM MET KEY SECONDARY ENDPOINT, WITH MAVORIXAFOR ACHIEVING CLINICAL & STATISTICAL SUPERIORITY OVER PLACEBO WHEN MEASURING TATALC Source text for Eikon: Further company coverage: